NEW YORK (GenomeWeb) – Interleukin Genetics today said that it will provide its genetic testing services to Isis Pharmaceuticals for a Phase II clinical study evaluating the novel therapeutic ISIS-APO(a)Rx in patients with high levels of lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.